Are We Applying AI at the Wrong End of Drug Development?
New FDA Guidance for Digitizing Preclinical Testing On April 10th, the FDA announced a plan to phase out animal testing requirements for investigational new drug (IND) applications1. This move underscores a growing trend to tackle the high cost and low success rates that plague drug development by improving in vitro and in silico approaches to predicting safety and efficacy in […]